Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002855 · ClinicalTrials.gov registry record · Phase 3
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 306
- Enrollment target
- 1
- Study location
NCT00002855: Completed Phase 3 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.
NCT00002855 is a Phase 3 study of Prostate Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 306 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002855, a Phase 3 study of Prostate Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 306 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
Conditions Studied
Interventions
- DRUG Bicalutamide
- DRUG Flutamide
- DRUG Doxorubicin hydrochloride
- DRUG Ketoconazole
- DRUG Estramustine Phosphate Sodium
Study Locations (1)
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 1996-08 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
What the finished NCT00002855 record still lists
NCT00002855 is an interventional study that assigns participants to a tested intervention. The registered 306 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bicalutamide is the first listed.
NCT00002855 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00002855 about?
NCT00002855 is a clinical study titled "Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. ...
What is the current status of trial NCT00002855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 306 participants. The study started on 1996-08. Estimated completion is 2005-06.
What conditions does trial NCT00002855 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00002855?
The interventions under investigation include: Bicalutamide (DRUG), Flutamide (DRUG), Doxorubicin hydrochloride (DRUG), Ketoconazole (DRUG), Estramustine Phosphate Sodium (DRUG).
Who is sponsoring clinical trial NCT00002855?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002855 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002855's enrollment target sits among peer trials
306 156th of 735 higher than 579 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05078970 · 306 participants · NA
Advancing Suicide Intervention Strategies for Teens During High Risk Periods
- NCT05843695 · 306 participants · NA
Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety
- NCT06057337 · 306 participants · NA
Families With Pride ("Familias Con Orgullo").
- NCT06498635 · 306 participants · Phase 3
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia